← Back to headlines
Outlook Therapeutics Appoints Kevin Lundquist as CFO Ahead of U.S. Commercial Launch of LYTENAVA™
Outlook Therapeutics has named Kevin Lundquist as its new Chief Financial Officer as the company prepares for the commercial rollout of its drug LYTENAVA™ in the United States.
27 Aug, 20:05 — 27 Aug, 20:05
Related Stories
Lionel Richie Hospitalized in ICU Following St. Louis Concert
46m ago
Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue
5h ago
Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases
8h ago
England Pharmacies to Offer Free Quick Cholesterol Screening Tests
16h ago